{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T04:06:18Z","timestamp":1747973178257,"version":"3.41.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.endien.2025.501544","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:23:35Z","timestamp":1747308215000},"page":"501544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteogenesis imperfecta type V: About a clinical case"],"prefix":"10.1016","volume":"72","author":[{"given":"Mar\u00eda Fernanda","family":"Reinoso Gomezcoello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Pav\u00f3n de Paz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Navea Aguilera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Gil Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Bueno Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guadalupe","family":"Guijarro de Armas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Merino Viveros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Antonio","family":"Rosado Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Iglesias Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Dur\u00e1n Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2025.501544_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/endrev\/bnab017","article-title":"Osteogenesis imperfecta: Mechanisms and signaling pathways connecting classical and rare OI types","volume":"43","author":"Jovanovic","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.endien.2025.501544_bib0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","article-title":"A single recurrent mutation in the 5\u2032-UTR of IFITM5 causes osteogenesis imperfecta type V","volume":"91","author":"Cho","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.endien.2025.501544_bib0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00198-022-06581-x","article-title":"Retrospective analyses of clinical features in 28 Chinese patients with type V osteogenesis imperfecta: new perspectives in an old issue","volume":"34","author":"Tan","year":"2023","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endien.2025.501544_bib0020","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3390\/ijms23042148","article-title":"The osteogenesis imperfecta type V mutant BRIL\/IFITM5 promotes transcriptional activation of MEF2, NFATc, and NR4A in osteoblasts","volume":"23","author":"Maranda","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.endien.2025.501544_bib0025","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/ajmg.a.36024","article-title":"Osteogenesis imperfecta type V: clinical and radiographic manifestations in mutation confirmed patients","volume":"161","author":"Kim","year":"2013","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.endien.2025.501544_bib0030","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/jbmr.2156","article-title":"A nonclassical IFITM5 mutation located in the coding region causes severe osteogenesis imperfecta with prenatal onset","volume":"29","author":"Hoyer-Kuhn","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endien.2025.501544_bib0035","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00256-011-1236-x","article-title":"Osteogenesis imperfecta type V","volume":"40","author":"Hui","year":"2011","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.endien.2025.501544_bib0040","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00223-021-00932-2","article-title":"Specific characteristic of hyperplastic callus in a larger cohort of osteogenesis imperfecta type V","volume":"110","author":"Zheng","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.endien.2025.501544_bib0045","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endien.2025.501544_bib0050","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.endinu.2018.05.015","article-title":"Efectos agudos y a largo plazo del tratamiento con zolendronato en pacientes adultos con osteog\u00e9nesis imperfecta. Estudio espa\u00f1ol observacional con 5 a\u00f1os de seguimiento","volume":"66","author":"Pav\u00f3n de Paz","year":"2019","journal-title":"Endocrinol Diabetes Nutr"},{"key":"10.1016\/j.endien.2025.501544_bib0055","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","article-title":"Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta","volume":"87","author":"Shapiro","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.endien.2025.501544_bib0060","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.4158\/EP151184.OR","article-title":"The clinical characteristics and efficacy of bisphosphonates in adult patients with osteogenesis imperfecta","volume":"22","author":"Xu","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.endien.2025.501544_bib0065","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1210\/clinem\/dgad035","article-title":"Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta","volume":"108","author":"Liu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501544_bib0070","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/biom11101493","article-title":"Osteogenesis imperfecta: current and prospective therapies","volume":"11","author":"Botor","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.endien.2025.501544_bib0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s13312-016-0830-3","article-title":"Worsening of callus hyperplasia after bisphosphonate treatment in type V osteogenesis imperfecta","volume":"53","author":"Ranganath","year":"2016","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.endien.2025.501544_bib0080","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.endien.2025.501544_bib0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","article-title":"Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study","volume":"14","author":"Leali","year":"2017","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.endien.2025.501544_bib0090","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.endien.2025.501544_bib0095","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4055\/cios20060","article-title":"Management of osteogenesis imperfecta: a multidisciplinary comprehensive approach","volume":"12","author":"Cho","year":"2020","journal-title":"Clin Orthop Surg"},{"key":"10.1016\/j.endien.2025.501544_bib0100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.11604\/pamj.2022.43.201.34702","article-title":"Effect of physiotherapy rehabilitation on osteogenesis imperfecta with a midshaft tibial fracture in the 11-year-old patient: a case report","volume":"43","author":"Nangliya","year":"2022","journal-title":"Pan Afr Med J"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018025000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018025000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:49:17Z","timestamp":1747900157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018025000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2530018025000617"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2025.501544","relation":{},"ISSN":["2530-0180"],"issn-type":[{"type":"print","value":"2530-0180"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteogenesis imperfecta type V: About a clinical case","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2025.501544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2025.501544","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501544"}}